Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Introduction Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers. Methods A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. Results Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). Discussion Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Morgan, A. R., Touchard, S., Leckey, C., O'Hagan, C., Nevado-Holgado, A. J., NIMA Consortium, et al. (2019). Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2019.03.007

Vancouver

Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ, NIMA Consortium, et al. Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2019. doi:10.1016/j.jalz.2019.03.007. PMID: 31047856.

BibTeX

@article{morgan2019-31047856,
  author  = {Morgan, A. R. and Touchard, S. and Leckey, C. and O'Hagan, C. and Nevado-Holgado, A. J. and {NIMA Consortium} and Barkhof, F. and Bertram, L. and others},
  title   = {{Inflammatory biomarkers in Alzheimer's disease plasma}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2019},
  doi     = {10.1016/j.jalz.2019.03.007},
  pmid    = {31047856},
  url     = {https://doi.org/10.1016/j.jalz.2019.03.007}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study identified several blood markers of inflammation and complement dysregulation that could distinguish people with Alzheimer's disease from controls and from those with mild cognitive impairment, and two markers plus age predicted progression from mild cognitive impairment to Alzheimer's. The authors state that further replication is needed before these markers can be used clinically, and no treatment is tested.

Study details

How this study scored 61/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 3 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multi-centre collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 61 of 100.61 of 100 points earned39 not earned

Published in a leading specialty journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 207 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 23.0 citations a year over 9 year(s) since 2019
Impact for its field and year 4 / 6 Cited 17.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 13 other studies in this library
Still being cited 3 / 4 Cited 72 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author B. Paul Morgan: h-index 102 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Oxford: institution h-index 2,205 (OpenAlex)
Multi-centre collaboration 3 / 3 OpenAlex lists 36 institution(s) in 12 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 31047856)
Free to read 2 / 2 Free to read
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

13 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Mild cognitive impairment

Also tagged “cerebrospinal”

822 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 822 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →